Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-yCD/mutTKSR39rep-ADP and fSRS in recurrent high-grade astrocytoma
NCT05686798Phase 1Recruiting
- Sponsor
- Henry Ford Health
- Start
- Nov 2022
- Primary completion
- Jan 2027
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label trial of ad5-ycd/muttksr39rep-adp in high-grade astrocytoma, sponsored by Henry Ford Health. Started Nov 2022; status: recruiting.
02
Drugs
ad5-ycd/muttksr39rep-adp
03
Conditions
high-grade astrocytoma
Beyond the preview
Go deeper on NCT05686798.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05686798.